BioSpace News Archive

Abivax (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for their lead drug candidate ABX464, allowing the initiation of clinical trials in the U.S. in patients with moderate-to-severe ulcerative colitis (UC).

Applied Genetic Technologies Corporation announced that it plans to release interim six-month data from the dose escalation groups, and an update of enrollment for its ongoing CNGB3 and CNGA3 Phase 1/2 clinical trials in patients with achromatopsia on January 23, 2020.

Misonix, Inc., a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, announced that it has commenced an underwritten public offering of its common stock.

ImmunoGen, Inc.,, a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced that it has commenced an offering of up to 7,250,000 American Depositary Shares representing 7,250,000 ordinary shares in an underwritten public offering in the United States.

Technavio has announced its latest market research report titled global resuscitation masks market 2019-2023.

Technavio has announced its latest market research report titled global heparin market 2020-2024

Zymeworks Inc. announced the pricing of its previously-announced underwritten public offering of 4,924,729 common shares and, in lieu of common shares to a certain investor, pre-funded warrants to purchase up to 1,075,271 common shares.

Autolus Therapeutics plc announced the pricing of an underwritten public offering in the United States of 7,250,000 American Depositary Shares representing 7,250,000 ordinary shares at a public offering price of $11.00 per ADS, for total gross proceeds of approximately $80.0 million.

New Coastal’s holistic approach to health and wellness is now bolstered by partner EndoCanna Health Inc., the creator of the Endo-Aligned cannabinoid formulation approach, with the release of tinctures and softgels with proprietary blends.